Commercialisation of SleepCogni into UK and US sleep clinic market

人们越来越认识到，我们的睡眠时间对我们的健康和幸福感有重要影响。近年来，我们越来越意识到睡眠对我们的身心健康的影响。即使一个晚上睡得不好或睡到很晚，也会影响一个人的情绪、警觉性和记忆力。睡眠不良的长期影响可能会导致一系列危及生命的疾病，如心血管疾病、肥胖和抑郁症。最近，疾病控制和预防中心将睡眠不足列为一种全球流行病。睡眠不足造成的经济成本巨大，并导致每年令人震惊的生产力损失；美国、日本、德国和英国分别损失4110亿美元、1380亿美元、600亿美元和500亿美元。不出所料，助眠市场是全球性的，要求很高，而且还在不断增长，预计到2023年将达到1019亿美元，Carg含量为6.5%(兰德欧洲，2016)。我们的使命是让世界上没有令人上瘾的安眠药，为每个人提供良好的睡眠，改善健康和幸福感。SleepCogni已经确定了临床上迫切需要一种帮助诊断、提供治疗和监测依从性的解决方案。SleepCogni系统为这一问题提供了一种创新的技术解决方案。SleepCogni开发了一种可穿戴的床边设备并获得了专利，该设备设计用于受试者的家中，将通过纵向数据为睡眠临床医生提供支持，从而实现完全知情的诊断。它还可以通过生物反馈系统提供个性化的光、声和触觉提示来治疗失眠。由于之前的创新英国基金，SleepCogni已经开始产生真正的动力。SleepCogni现在(I)是一种经过临床验证的治疗方法，(Ii)FDA注册，(Iii)已经招募了四家睡眠诊所进行测试。该项目将使SleepCogni进入开发的最后阶段，加快商业化进程，并利用之前的投资。

The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression. Sleep deprivation was recently identified by Centers for Disease Control and Prevention as a global epidemic.The economic costs of poor sleep are huge and lead to a staggering annual productivity loss; US $411bn, Japan $138bn, Germany $60bn and UK $50bn. Unsurprisingly, the sleep aid market is global, demanding and growing, and expected to hit $101.9bn by 2023 with 6.5% CARG (RAND Europe, 2016).Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.SleepCogni has identified an urgent clinical need for a solution that aids diagnostics, provides treatment and monitors adherence. The SleepCogni system provides an innovative technological solution to this problem. SleepCogni has developed and patented a wearable and bedside device designed to be used within a subject's home, which will provide support to sleep clinicians, through longitudinal data, enabling a fully informed diagnosis. It can also deliver a treatment for insomnia using light, sound and tactile cues personalised through a biofeedback system.Due to their previous Innovate UK grant, SleepCogni has started to generate real momentum. SleepCogni is now (i) a clinically proven treatment, (ii) FDA registered and (iii) has enrolled four sleep clinics for testing. This project would allow SleepCogni to move to the final stage of development, accelerating commercialisation and capitalising on previous investment.